Intellia Therapeutics Completes Enrollment in Phase 3 MAGNITUDE-2 Trial of Nexiguran Ziclumeran (Nex-z) for Patients with Hereditary Transthyretin Amyloidosis with Polyneuropathy (ATTRv-PN)
Key Highlights
- ➤MAGNITUDE-2 completes enrollment for approximately 60 ATTRv-PN patients
- ➤Nex-z trial uses a single 55 mg infusion versus placebo
- ➤Primary endpoints assess neuropathy impairment at month 18 and TTR at day 29
- ➤Nex-z is also in Phase 3 MAGNITUDE trial for ATTR-CM
- ➤FDA granted nex-z Orphan Drug and RMAT designations
Expert Statements
John Leonard, M.D., President and Chief Executive Officer of Intellia Therapeutics
“We are grateful to the patients, caregivers and investigators who are participating in MAGNITUDE-2. Completing enrollment in this trial is a pivotal step toward bringing a potentially transformative one-time treatment to people living with ATTRv-PN, a debilitating and life-threatening disease with significant unmet need.”
John L. Berk, M.D., Professor Emeritus of Medicine, Amyloidosis Center, Boston University School of Medicine
“While disease-modifying therapies have advanced the standard of care for ATTRv-PN, many patients continue to progress. An agent that can quickly, substantially and consistently reduce TTR after a single dose would be a meaningful advancement for patients. Completing enrollment in the MAGNITUDE-2 trial is an exciting milestone toward that goal.”
CAMBRIDGE, Mass., Nov. 04, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core technologies, today announced the completion of enrollment in MAGNITUDE-2, the Phase 3 clinical trial of nex-z in patients with ATTRv-PN. Nex-z is an investigational in vivo CRISPR-based therapeutic candidate designed to inactivate the TTR gene in the liver, thereby preventing the production of transthyretin (TTR) protein. Nex-z offers the possibility of halting and reversing disease by driving a rapid, deep, consistent and potentially lifelong reduction in TTR protein after a one-time treatment.
“We are grateful to the patients, caregivers and investigators who are participating in MAGNITUDE-2,” said John Leonard, M.D., Intellia President and Chief Executive Officer. “Completing enrollment in this trial is a pivotal step toward bringing a potentially transformative one-time treatment to people living with ATTRv-PN, a debilitating and life-threatening disease with significant unmet need.”
Get started
Create a free account to read the full story.